Search Results for:

Deal Watch: Henlius Licenses Rituximab and Trastuzumab Products to Abbott in Brazil

Earlier this week, Shanghai Henlius Biotech, Inc. announced that it has entered into a semi-exclusive license agreement with Abbott Operations Uruguay S.R.L. for the commercialization of HANLIKANG (rituximab) and HANQUYOU (trastuzumab, trade name in Europe: Zercepac®), two products developed by Henlius, in Brazil.  According to the announcement, Abbott will pay…

Read More